UBS AM
ORKA

UBS AM’s Oruka Therapeutics ORKA Stock Holding History

UBS AM’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.93M Buy
104,310
+87,408
+517% +$5.82M ﹤0.01% 1248
2026
Q1 		$829K Buy
16,902
+2,658
+19% +$92.4K ﹤0.01% 2409
2025
Q4 		$432K Buy
+14,244
New +$397K ﹤0.01% 2354

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS AM's ORKA Position: Q2 2026 in Review

UBS AM increased its Oruka Therapeutics (ORKA) stake by 517% in Q2 2026, buying an estimated $5.82M and bringing the position to 104,310 shares worth $9.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1248.

UBS AM first reported a position in ORKA in Q4 2025 and has held it in 3 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • UBS AM held 104,310 shares of Oruka Therapeutics worth $9.93M as of Q2 2026.
  • UBS AM bought 87,408 Oruka Therapeutics shares in Q2 2026, an estimated $5.82M.
  • Oruka Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1248 holding.
  • UBS AM first reported a position in Oruka Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.